市场调查报告书
商品编码
1471293
智慧胰岛素笔市场:按类型、可用性、应用和最终用户 - 2024-2030 年全球预测Smart Insulin Pen Market by Type (First Generation Pens, Second Generation Pens), Usability (Prefilled, Reusable), Application, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年智慧胰岛素笔市场规模为1.4962亿美元,预计2024年将达1.6995亿美元,2030年将达3.7764亿美元,复合年增长率为14.14%。
智慧胰岛素笔,也称为数位胰岛素笔,是先进的医疗设备,经过精心设计,可帮助糖尿病患者准确管理和监测胰岛素剂量。与传统胰岛素笔不同,智慧胰岛素笔采用先进技术,使糖尿病管理变得更容易。随着全球糖尿病患者数量的不断增加以及人们对糖尿病的认识不断提高,智慧胰岛素笔的使用情况显着改善。技术的进步和研发投资的增加也增加了智慧胰岛素笔的可用性。然而,与笔相关的高成本和技术困难可能会限制该产品在全球的可用性和使用。此外,正在研究开发使用寿命长且可以连续几天注射胰岛素的笔,这可能为智慧胰岛素笔市场提供重大机会。
主要市场统计 | |
---|---|
基准年[2023] | 1.4962亿美元 |
预测年份 [2024] | 16995万美元 |
预测年份 [2030] | 37764万美元 |
复合年增长率(%) | 14.14% |
2 代笔为糖尿病管理提供了更好的控制
与传统胰岛素输送法相比,第一代智慧胰岛素笔代表了一项重大技术飞跃。它具有一些小的技术付加,例如记忆功能,可以让使用者知道先前的剂量和时间。这些笔易于使用,同时减少了手动记录胰岛素摄取量。这些笔旨在帮助患者遵守规定的胰岛素治疗方案并改善血糖值。第二代智慧胰岛素笔配备了蓝牙和USB连接等先进技术,使它们能够与其他设备无线通讯资料,从而更轻鬆地管理和追踪胰岛素的使用情况。支援蓝牙的第二代笔可与执行糖尿病管理应用程式的智慧型手机和平板电脑无缝连接。这种笔到应用程式的无线资料传输可以实现个人化的剂量调整、提醒以及患者胰岛素给药历史的完整日誌。提供即时更新和详细的可视化,以增强患者自我管理的信心。 USB 连接的智慧型胰岛素笔为资料便携性和可访问性带来了新的维度。您可以透过USB连接埠将其连接到电脑和笔记型电脑等装置并轻鬆传输资料。这对于改善患者咨询和调整治疗计划以优化血糖控制至关重要。
易于使用:采用可重复使用的智慧胰岛素笔具有成本效益
预填充智慧胰岛素笔非常适合寻求便利和简单的患者。预填充胰岛素笔预先装有药筒,无需在使用前手动为笔充注胰岛素。使用者友善的设计降低了污染和剂量计算错误的风险。另一方面,可重复使用的智慧胰岛素笔适合那些优先考虑环境永续性和成本效益而不是便利性的患者。这些笔需要使用者手动更换胰岛素筒。预填充笔较舒适,不易出现使用者错误,而长期来看,可重复使用的笔更具成本效益且环保。
应用 增加智慧型胰岛素笔的使用,以克服 II 型糖尿病的负担
I型糖尿病,也称为胰岛素依赖型糖尿病,需要严格的血糖值监测。功效和便利性是选择胰岛素输送系统时的重要因素。这就是智慧胰岛素笔成为游戏规则改变者的地方,它提供高精度,确保胰岛素治疗的依从性,并最大限度地降低错误和低血糖的风险。典型的胰岛素抗性 II 型糖尿病患者必须维持足够的胰岛素水平。 II 型糖尿病是进行性糖尿病,因此胰岛素治疗随着时间的推移变得更加重要。这就是为什么智慧胰岛素笔旨在提供便利且个人化的胰岛素管理解决方案。 I 型糖尿病需要更频繁和更精确的剂量。因此,I型糖尿病智能胰岛素笔注重剂量记录和定时提醒。由于 II 型糖尿病是进行性糖尿病,并且存在不同程度的胰岛素阻抗,因此笔的设计具有预填充胰岛素药筒和可定制剂量等功能。
最终用户:扩大智慧胰岛素笔在家庭医疗环境中的使用
门诊手术中心 (ASC) 是一家提供当天手术治疗的医疗机构,包括诊断和预防程序。其主要原因是智慧胰岛素笔提高了准确性和即时追踪功能,可以更好地病患监测和糖尿病管理。在占最终用户群体很大一部分的家庭护理环境中,喜欢在家中控製糖尿病的人脱颖而出。智慧胰岛素笔的易用性、经济性和连接性使其深受家庭用户的欢迎。智慧胰岛素笔的重要最终使用者是作为基层医疗中心的医院和诊所。这些设备因其剂量准确、用户友好的功能以及无线监测患者胰岛素水平的能力而成为医院环境中的首选。这可以缩短住院时间并改善患者的治疗效果。 ASC 更喜欢准确性和即时跟踪,而家庭用户则重视价格实惠和易用性。医院和诊所重视该设备透过精确剂量和即时监测改善患者治疗效果的能力。
区域洞察
由于糖尿病盛行率上升、医疗费用飙升以及主要市场参与者的存在,美洲的市场状况正在显着波动。该地区各国正在采取措施,提高人们对智慧胰岛素笔相对于传统方法的便利性和有效性的认识,这也有助于市场成长。由于人口老化和先进糖尿病管理系统意识的增强,智慧胰岛素笔的使用在欧盟国家不断增加。改善糖尿病管理和改善医疗基础设施的立法正在支持这一领域的投资。中东和非洲糖尿病患者数量的不断增加引发了人们对智慧胰岛素笔的兴趣。在监管方面,各国政府正在製定政策,为公民提供创新的医疗保健解决方案,这可能会加速这些新兴市场的成长。亚太地区人口众多,是对抗糖尿病的潜在客户群,预计将成为智慧胰岛素笔不断成长的市场。各国政府对现代糖尿病治疗方法的需求变得越来越敏感,从而推动了对智慧胰岛素笔的需求。
FPNV定位矩阵
FPNV定位矩阵对于评估智慧胰岛素笔市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对智慧胰岛素笔市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.智慧胰岛素笔市场规模及预测是多少?
2.智慧胰岛素笔市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3.智慧胰岛素笔市场的技术趋势和法规结构是什么?
4.智慧胰岛素笔市场主要厂商的市场占有率是多少?
5.进入智慧胰岛素笔市场合适的型态和策略手段是什么?
[189 Pages Report] The Smart Insulin Pen Market size was estimated at USD 149.62 million in 2023 and expected to reach USD 169.95 million in 2024, at a CAGR 14.14% to reach USD 377.64 million by 2030.
The smart insulin pen, referred to as a digital insulin pen, is a sophisticated medical device intricately designed to aid people with diabetes in accurately administering and monitoring their insulin dosage. Unlike the traditional insulin pens, the smart insulin pen utilizes advanced technology to facilitate effortless diabetes management. The global rise in diabetes cases and awareness about the disease have significantly improved the use of smart insulin pens. Technological advancements and increased investment in research and development activities also enhance the availability of smart insulin pens. However, high costs associated with the pens and technical difficulties may limit the availability and usage of products worldwide. Furthermore, ongoing research into developing pens with prolonged lifespans and multi-day insulin delivery capabilities can provide a substantial opportunity for smart insulin pens market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 149.62 million |
Estimated Year [2024] | USD 169.95 million |
Forecast Year [2030] | USD 377.64 million |
CAGR (%) | 14.14% |
Type: Second-generation pens offer higher control to diabetes management
The first-generation smart insulin pens represent a significant technological leap over traditional insulin delivery methods. They incorporate minor technological additions, such as memory functions, to provide users with information on their previous dosage and time. These pens are simple to use while providing relief in manual recordkeeping for insulin intake. They aim to help patients adhere to their prescribed insulin regimen, improving glycemic outcomes. Second-generation smart insulin pens are equipped with advanced technology such as bluetooth and USB connectivity, thus enabling them to wirelessly communicate data to other devices for easier management and tracking of insulin usage. Bluetooth-enabled second-generation pens offer seamless connectivity with smartphones and tablets running diabetes management apps. This wireless data transfer from the pen to the app allows personalized dose adjustments, reminders, and a complete log of the patient's insulin administration history. It provides real-time updates and detailed visualizations, increasing patients' confidence in self-managing their condition. USB-connected smart insulin pens add another dimension to data portability and accessibility. They can be connected to devices such as computers and laptops via a USB port for easy data transfer. This provides healthcare practitioners valuable insights into their patients' insulin usage, which can be crucial for improved patient counseling and tailoring the treatment plan for optimizing glucose control.
Usability: Adoption of reusable smart insulin pens due to its cost-efficiency
Prefilled smart insulin pens are ideal for individuals seeking convenience and simplicity. Prefilled smart insulin pens come with a preloaded medication cartridge, eliminating the need to load insulin into the pen before use manually. The user-friendly design reduces the risk of contamination and potential mistakes in dosage calculation. On the other hand, reusable smart insulin pens are suitable for patients who prioritize environmental sustainability and cost-effectiveness above convenience. These pens require users to replace insulin cartridges manually. The prefilled pens offer greater comfort and are less prone to user error, whereas reusable pens are more cost-effective and environmentally friendly in the long run.
Application: Increasing use of smart insulin pens to overcome the burden of Type II diabetes
Type I diabetes, also known as insulin-dependent diabetes, requires stringent blood glucose level monitoring. Efficacy and convenience become crucial factors in choosing an insulin delivery system. That's where the smart insulin pen becomes a game-changer, offering high levels of precision, adherence to insulin regimes, and minimizing the risks of errors and hypoglycemia. Sufferers of Type II diabetes, who typically have insulin resistance, must maintain adequate insulin levels. Due to the progressive nature of Type II diabetes, insulin therapy becomes critical over time. Thus, smart insulin pens are designed to provide a convenient and personalized insulin management solution. Type I diabetes requires more frequent and precise doses. Hence, smart insulin pens for Type I diabetes are focused more on dose recording and timing reminders. For Type II diabetes, due to its progressive nature and varying insulin resistance levels, pens are designed with features like prefilled insulin cartridges and customizable doses.
End-User: Proliferating usage of smart insulin pens in home healthcare settings
Ambulatory surgical centers (ASCs) are healthcare installations that provide same-day surgical care, including diagnostic and preventive procedures. They have shown a growing preference for using smart insulin pens, primarily due to their enhanced accuracy and real-time tracking features that allow better patient monitoring and improved diabetes management. A significant section of the end-user segment, home care settings, is marked by people who prefer to manage their diabetes at home. The ease of use, affordability, and connectivity of smart insulin pens have made them increasingly popular among home users. Hospitals and clinics, as primary care centers, constitute significant end-users of smart insulin pens. These devices are preferred in hospital settings for their precise dosing, user-friendly features, and the ability to wirelessly monitor patient's insulin levels. This can help reduce hospital stay length and improve patient outcomes. ASCs prefer precision and real-time tracking, whereas home users value affordability and ease of use. Hospitals & clinics appreciate the devices' ability to improve patient outcomes through precise dosing and real-time monitoring.
Regional Insights
The Americas have a significant landscape in the smart insulin pen market owing to rising diabetes prevalence, high healthcare expenditure, and the presence of key market players. Countries in the region also contribute to the market growth, incorporating steps to increase awareness about the convenience and effectiveness of smart insulin pens compared to traditional methods. Across EU nations, the rising aging population and increasing awareness of advanced diabetes management systems have escalated the reach of smart insulin pens. Legislation for improved diabetes management and healthcare infrastructure propels investment in the sector. The increasing cases of diabetes in the Middle East and Africa have spiked interest in smart insulin pens. In terms of regulation, governments have initiated policies to deliver innovative healthcare solutions to their citizens, potentially accelerating growth in these emerging markets. The APAC region is expected to be the growing market for smart insulin pens due to their teeming populations, which are large pools of potential customers grappling with diabetes. Governments are becoming increasingly sensitive to the need for modern diabetes treatment methods, driving the demand for smart insulin pens.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Smart Insulin Pen Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Smart Insulin Pen Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Smart Insulin Pen Market, highlighting leading vendors and their innovative profiles. These include B. Braun SE, Becton, Dickinson and Company, Berlin-Chemie AG, Bigfoot Biomedical Inc., BIOCORP Production, Dexcom, Inc., Diamesco Co., Ltd., Eli Lilly and Company, Emperra GmbH, F. Hoffmann-La Roche AG, HTL-Strefa, Inc., Insulet Corporation, IQVIA Inc., Jiangsu Deflu Medical Device Co. Ltd., Medtronic PLC, Novo Nordisk A/S, Owen Mumford Ltd., pendiq GmbH, Sanofi S.A., Tandem Diabetes Care Inc., and Ypsomed Holding AG.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Smart Insulin Pen Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Smart Insulin Pen Market?
3. What are the technology trends and regulatory frameworks in the Smart Insulin Pen Market?
4. What is the market share of the leading vendors in the Smart Insulin Pen Market?
5. Which modes and strategic moves are suitable for entering the Smart Insulin Pen Market?
TABLE 3